Ultrasound-activated Nanoparticles Kill Liver Cancer and Activate Immune System

A new ultrasound-guided nanotherapy wipes out liver tumors while training the immune system to keep them from coming back.

The study, published in Nano Today, introduces a biodegradable nanoparticle system that combines sonodynamic therapy and cell death induction (ferroptosis) to treat hepatocellular carcinoma, the most common type of liver cancer.

The platform uses ultrasound-triggered generation of reactive oxygen species and controlled release of the blood thinner warfarin to trigger cancer cell death and stimulate anti-tumor immunity.

Hepatocellular carcinoma is one of the most challenging types of liver cancer to treat due to poor immune responsiveness and high recurrence.

While ferroptosis inducement, an iron-dependent form of regulated cell death, has shown promise, its standalone effectiveness is limited.

The study’s strategy enhances ferroptosis by combining ultrasound-activated reactive oxygen species with warfarin, an inhibitor of VKORC1L1, a key enzyme that helps cells neutralize oxidative damage.

Nanoplatform Design and Mechanism

Researchers synthesized a pseudo-conjugated sonodynamic polymer (BSD) via a Palladium-catalyzed coupling method.

This polymer was co-assembled with warfarin and DSPE-PEG2000 to form NP-BSD@WFR, a nanoparticle featuring a biodegradable core and a PEG shell, which promotes stability and passive tumor targeting via the enhanced permeability and retention (EPR) effect.

Upon ultrasound exposure, the nanoparticles disintegrate rapidly, releasing both ROS and warfarin in the tumor microenvironment. This dual action both damages cancer cells and disrupts their antioxidant defenses, tipping the balance toward ferroptotic cell death.

Killing Liver Cancer Cells Through ROS and Ferroptosis

Tests in hepatocellular carcinoma cell lines (HUH-7, HepG2, H22) showed that NP-BSD@WFR was efficiently taken up and, when activated by ultrasound, generated substantial ROS.

This led to glutathione (GSH) depletion, downregulation of glutathione peroxidase 4 (GPX4), and accumulation of lipid peroxides, all key hallmarks of ferroptosis.

Compared to controls, cells treated with NP-BSD@WFR plus ultrasound exhibited significantly higher apoptosis and reduced colony formation. 3D tumor spheroid models confirmed this enhanced cytotoxicity.

Tumor Targeting and Immune Activation

In a subcutaneous hepatocellular carcinoma mouse model, NP-BSD@WFR showed strong tumor accumulation due to the EPR effect.

Upon systemic administration and ultrasound activation, the treatment achieved 92 % tumor inhibition over 12 days, with no significant weight loss or visible organ toxicity.

Importantly, the therapy induced immunogenic cell death, evidenced by:

• Increased dendritic cell (DC) maturation
• Elevated levels of CD8+ T cell infiltration
• Enhanced systemic T cell activation in spleens and lymph nodes

These findings suggest that, as well as attacking tumor cells directly, the platform also primes the immune system to recognize and attack cancer.

A Future in Liver Cancer Treatment

This study demonstrates a promising approach to treating liver cancer by combining sonodynamic therapy with ferroptosis amplification and immune stimulation.

The biodegradable design, targeted activation, and robust immune engagement make NP-BSD@WFR a strong candidate for further development.

While the results are encouraging, further studies will be necessary to assess long-term safety, refine dosing, and investigate efficacy in other tumor types.

Journal Reference

Wang P., et al. (2025). Nanoplatform for ferroptosis-based liver cancer therapy via sonodynamic activation and immune response. Nano Today, 66, 102891. DOI: 10.1016/j.nantod.2025.102891